INVO Fertility shares jumped Monday after the fertility services company reported second-quarter fiscal 2026 diluted EPS of $0.35 and net income of $0.89 million, helped by an approximately $2.5 million remeasurement gain tied to its Birmingham, Alabama clinic acquisition. Revenue rose 17% year over year to $2.18 million, with the first full-quarter contribution from Family Beginnings and growth initiatives across its network lifting consolidated clinic revenue 18% to $2.17 million, while clinic-level Adjusted EBITDA roughly doubled sequentially to about $333,000. Published Wall Street consensus figures differed across market reports, with expected losses ranging from $0.65 to $0.70 a share and revenue estimates from $2.4 million to $2.71 million, but the company still beat profit expectations and missed revenue forecasts. CEO Steve Shum said the clinic platform remained profitable before corporate and public company expenses and said INVO plans organic growth, broader use of its corporate infrastructure and disciplined acquisitions of established, profitable fertility practices. Shares were up 53.52% at $1.49 in Monday afternoon trading in one update, while later recaps cited gains as high as 145% amid unusually heavy volume.